Literature DB >> 19822304

Early and late neurological complications after reduced-intensity conditioning allogeneic stem cell transplantation.

Pere Barba1, Jose Luis Piñana, David Valcárcel, Luis Querol, Rodrigo Martino, Anna Sureda, Javier Briones, Julio Delgado, Salut Brunet, Jorge Sierra.   

Abstract

Neurological complications (NC) after allogeneic hematopoietic stem cell transplantation (allo-HSCT) are common and life-threatening in most cases. They may involve either the central (CNS) or peripheral nervous system (PNS). The aim of this study was to describe incidence and characteristics of NC after reduced-intensity conditioning allo-HSCT (allo-RIC), an unexplored setting. For this purpose, we reviewed 191 consecutive patients who underwent this procedure at our institution between January 1999 and December 2006. The median follow-up for survivors was 48 months (3-98 months). RIC included fludarabine (Flu) 150 mg/m(2) in combination with busulfan (Bu) 8-10mg/kg (n=61), melphalan (Mel) 70-140 mg/m(2) (n=119), cyclophosphamide (Cy) 120 mg/kg (n=7), or low-dose total body irradiation (TBI) 2Gy (n=4). Graft-versus-host disease (GVHD) prophylaxis consisted of cyclosporine A (CsA) in combination with methotrexate (MTX; n=134) or mycophenolate mofetil (MMF; n=52). Twenty-seven patients (14%) developed a total of 31 NC (23 CNS and 8 PNS) for a 4-year cumulative incidence of 16% (95% confidence interval [CI] 11-23). CNS complications included nonfocal encephalopathies in 11 patients, meningoencephalitis in 5 patients, and stroke or hemorrhage in 4. PNS complications consisted of 5 cases of mononeuropathies and 3 cases of polyneuropathies. Drug-related toxicity was responsible for 10 of the 31 events (32%) (8 caused by CsA). Interestingly, 14 of the 23 CNS events (61%) and only 1 of the 8 PNS complications (13%) appeared before day +100 (P=.01). Overall, patients presenting NC showed a trend for higher 1-year nonrelapse mortality (NRM) (37% versus 20%, P=.08). In patients with CNS involvement, 1-year NRM was significantly worse (42% versus 20%, P=.02). CNS NC also had a negative impact on 4-year overall survival (OS; 33% versus 45%, P=.05). In conclusion, our study showed that NC are observed after allo-RIC and have diverse features. NC affecting the CNS have earlier onset and worse outcome than those involving the PNS.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19822304     DOI: 10.1016/j.bbmt.2009.07.013

Source DB:  PubMed          Journal:  Biol Blood Marrow Transplant        ISSN: 1083-8791            Impact factor:   5.742


  18 in total

1.  Neurologic complications after allogeneic hematopoietic stem cell transplantation: risk factors and impact.

Authors:  M R Dowling; S Li; B R Dey; S L McAfee; H R Hock; T R Spitzer; Y-B Chen; K K Ballen
Journal:  Bone Marrow Transplant       Date:  2017-11-13       Impact factor: 5.483

2.  Cerebrovascular disease after allogeneic hematopoietic stem cell transplantation: incidence, risk, and clinical outcome.

Authors:  Ting-An Lin; Jyh-Pyng Gau; Yao-Chung Liu; Po-Shen Ko; Hao-Yuan Wang; Sheng-Hsuan Chien; Chia-Jen Liu; Liang-Tsai Hsiao; Tzeon-Jye Chiou; Jin-Hwang Liu
Journal:  Int J Hematol       Date:  2019-03-12       Impact factor: 2.490

Review 3.  Toward a Better Understanding of the Atypical Features of Chronic Graft-Versus-Host Disease: A Report from the 2020 National Institutes of Health Consensus Project Task Force.

Authors:  Geoffrey D E Cuvelier; Michelle Schoettler; Nataliya P Buxbaum; Iago Pinal-Fernandez; Marc Schmalzing; Jörg H W Distler; Olaf Penack; Bianca D Santomasso; Robert Zeiser; Klemens Angstwurm; Kelli P A MacDonald; W Taylor Kimberly; Naomi Taylor; Ervina Bilic; Bernhard Banas; Maike Buettner-Herold; Namita Sinha; Hildegard T Greinix; Joseph Pidala; Kirk R Schultz; Kirsten M Williams; Yoshihiro Inamoto; Corey Cutler; Linda M Griffith; Stephanie J Lee; Stefanie Sarantopoulos; Steven Z Pavletic; Daniel Wolff
Journal:  Transplant Cell Ther       Date:  2022-05-31

4.  Central and peripheral nervous system immune mediated demyelinating disease after allogeneic hemopoietic stem cell transplantation for hematologic disease.

Authors:  Anna Maria Delios; Marc Rosenblum; Ann A Jakubowski; Lisa M DeAngelis
Journal:  J Neurooncol       Date:  2012-08-23       Impact factor: 4.130

5.  Neurological complications of transplantation: part I: hematopoietic cell transplantation.

Authors:  Amy A Pruitt; Francesc Graus; Myrna R Rosenfeld
Journal:  Neurohospitalist       Date:  2013-01

6.  Muscle cramps and neuropathies in patients with allogeneic hematopoietic stem cell transplantation and graft-versus-host disease.

Authors:  Peter D Kraus; Daniel Wolff; Oliver Grauer; Klemens Angstwurm; Sven Jarius; Klaus P Wandinger; Ernst Holler; Wilhelm Schulte-Mattler; Ingo Kleiter
Journal:  PLoS One       Date:  2012-09-17       Impact factor: 3.240

7.  Severe fludarabine neurotoxicity after reduced intensity conditioning regimen to allogeneic hematopoietic stem cell transplantation: a case report.

Authors:  Claudio Annaloro; Antonella Costa; Nicola S Fracchiolla; Gabriella Mometto; Silvia Artuso; Giorgia Saporiti; Elena Tagliaferri; Federica Grifoni; Francesco Onida; Agostino Cortelezzi
Journal:  Clin Case Rep       Date:  2015-06-11

8.  Autoimmune Demyelinating Polyneuropathy as a Manifestation of Chronic Graft-versus-Host Disease after Adult Cord Blood Transplantation in a Patient with Chronic Lymphocytic Leukemia.

Authors:  Fredrick Hogan; Melhem Solh
Journal:  Case Rep Hematol       Date:  2014-09-14

9.  Complete neurologic and cognitive recovery after plasmapheresis in a patient with chronic inflammatory demyelinating polyneuropathy after allogeneic hematopoietic stem cell transplantation.

Authors:  Ursula Vogl; Gerda Leitner; Assunta Dal-Bianco; Marija Bojic; Margit Mitterbauer; Werner Rabitsch; Peter Kalhs; Axel Schulenburg
Journal:  Wien Klin Wochenschr       Date:  2016-02-26       Impact factor: 1.704

Review 10.  Epileptic Seizures After Allogeneic Hematopoietic Stem Cell Transplantation.

Authors:  Zhuo Wang; Munan Zhao; Sujun Gao
Journal:  Front Neurol       Date:  2021-07-16       Impact factor: 4.003

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.